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Abstract
Background: Pharmacological and clinical differences between insulin glargine and NPH insulin may translate into
differences in patient reported outcomes, but existing data are equivocal.
Methods: In this 48-week, open-label, randomized, multi-center, crossover phase IV trial, insulin naïve type 2 diabetes
patients with blood glucose not at target on oral hypoglycemic agents had basal insulin added to their treatment
regimen. A total of 343 patients were randomized to either receive insulin glargine (n = 176; sequence A) or neutral
protamine Hagedorn (NPH) insulin (n = 167; sequence B) in period 1 (weeks 1–24) and vice versa in period 2 (weeks
25–48). The primary objective was to assess patient reported outcomes using a composite Diabetes Related Quality of
Life (DRQoL) score based on an unweighted Insulin Treatment Experience Questionnaire (ITEQ) score, a Problem Areas
in Diabetes (PAID) questionnaire score, and the mental health score in the Short Form (SF)-12® Health Survey, analyzed
by analysis of covariance (ANCOVA).
Results: Patients (mean age 62.3 ± 9.0; 39.5 % female) had a mean diabetes duration of 9.6 ± 5.9 years, a mean baseline
HbA1c of 8.15 ± 0.72 %, and a mean fasting blood glucose (FBG) level of 9.37 ± 2.19 mmol/L. A total of 229 patients
were available for primary endpoint evaluation (modified intention to treat population). Combining all data from both
periods for each insulin treatment, on a 0–100 scale, the mean DRQoL score was 69.6 (±9.04) with insulin glargine and
70.0 (±9.40) with NPH insulin. Neither an effect of treatment with insulin glargine vs NPH insulin (p = 0.31) nor a period
effect (p = 0.96), nor a sequence effect (p = 0.76) was observed using ANCOVA.
Conclusions: The results show that in a patient population with sub-optimal glycemic control at baseline, and
a low target achievement rate together with a low rate of hypoglycemia, differences in the patient reported
outcomes evaluated in this study were negligible between insulin glargine and NPH insulin.
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Background
It is well-established that achieving adequate glycemic
control reduces the risk of cardiovascular complications in
patients with type 2 diabetes [1, 2]. While oral antihyper-
glycemic treatments are often sufficient for reducing blood
glucose levels in newly diagnosed patients, the progressive
nature of the disease eventually requires insulin to be
added to maintain glycemic control [3]. Initiation of such
treatment can either proceed by administration of insulin
as a monotherapy, or by the addition of long-acting insu-
lins such as neutral protamine Hagedorn (NPH) insulin or
insulin glargine to the oral regimen (basal insulin sup-
ported oral therapy; BOT) [4, 5].
While NPH insulin has been shown to effectively reduce
blood glucose levels, its peak in activity at around 4–6 h
after administration can result in hypoglycemia [6–8]. In
comparison, insulin glargine has a much smoother activity
profile, resulting in a lower incidence of hypoglycemic
events [6, 7, 9–11]. Another important factor to be taken
into account when initiating BOT is the duration of NPH
activity of only 12–16 h, often resulting in the necessity of
twice daily injections. In contrast, the prolonged activity
of insulin glargine means that a single daily injection is
sufficient for maintaining adequate glucose control. Since
risk of hypoglycemia, reduction in lifestyle flexibility,
weight gain, and management of injections all have been
reported to contribute to the reluctance of patients to take
insulin (psychological insulin resistance), the named dif-
ferences between these two insulin regimens could be sig-
nificant [12–14].
There are only two studies to date that included an in-
vestigation of treatment satisfaction when adding insulin
glargine versus NPH insulin to oral therapy in patients
with type 2 diabetes. Both, Eliaschewitz et al. and Witthaus
et al. demonstrated slightly higher treatment satisfaction
with insulin glargine (p < 0.02 and p = 0.0634, respectively)
[8, 15]. Observational data (LIVE-DE) retrospectively taken
from questionnaires regarding insulin treatment satisfac-
tion and psychological impact has also indicated a trend
towards improved quality of life for patients receiving insu-
lin glargine in comparison to NPH insulin [16]. However, it
is clear that further study is required in order to clarify the
differences between these two treatments.
Therefore, the primary objective of this study was to in-
vestigate the impact of insulin glargine versus NPH insulin
on a composite Diabetes Related Quality of Life score
(DRQoL), consisting of a standardized and unweighted In-
sulin Treatment Experience Questionnaire Score (ITEQ), a
Problem Areas in Diabetes (PAID) questionnaire score, and
the mental health score in the Short Form (SF)-12® Health
Survey, in a randomized controlled study. The specific
combination of these scores allows for evaluation of a wide
variety of PROs, including general quality of life, diabetes-
related emotional distress, and overall mental health.
Patients and methods
The investigation reported here was a 51-week (2 weeks of
screening, 2 × 24 weeks treatment, 1 week follow-up),
open-label, randomized, multi-center, crossover phase
IV trial in insulin naïve type 2 diabetes patients with in-
sufficient metabolic control and HbA1c values ≥7.0 %
and ≤10.0 % (to decrease the likely need for prandial in-
sulin supplementation) despite treatment with oral
hypoglycemic agents (OHAs). The study protocol was
conducted in accordance with good clinical practice
and the Declaration of Helsinki, was approved by the
Ethics Committee of the Landesärztekammer Baden-
Württemberg (Stuttgart, Germany) on May 19th 2009,
and registered with clinicaltrials.gov (NCT00941369).
All patients provided written informed consent prior to
inclusion.
Patient selection
Patients of either gender (aged 18–80 years) with type 2
diabetes mellitus according to the American Diabetes
Association criteria [17], were considered eligible for the
study. Further inclusion criteria were a body mass index
(BMI) of >22 to <40 kg/m2, HbA1c of ≥7.0 to ≤10.0 %,
and fasting blood glucose (FBG) of ≥120 mg/dL
(6.7 mmol/L).
In order to allow for an accurate comparison of the two
types of insulin, patients were excluded from the study if
they had received treatment with any insulin within the
3 months prior to inclusion, treatment with more than
two OHAs within the 4 weeks prior to inclusion, or con-
tinuous treatment with thiazolidinediones or glucagon-
like peptide (GLP)-1 receptor agonists. Other factors that
may significantly affect quality of life or emotional well-
being were also indications for exclusion from the study.
These included a history of ketoacidosis, a history of drug
or alcohol abuse, diabetic retinopathy with surgical treat-
ment (laser photocoagulation or vitrectomy) in the
3 months prior to study entry or which may require surgi-
cal treatment within 3 months, prior pancreatectomy, im-
paired hepatic function, impaired renal function, current
treatment for a psychiatric illness (not further specified),
systemic corticoid treatment for more than 2 months,
prior bariatric surgery, or major dietary changes for weight
management during the last 3 months resulting in weight
reduction of >5 kg.
Study design and treatments
The study consisted of a two-week screening phase,
followed by two 24-week treatment periods, without a
washout period in between. After the second treatment
period, patients were followed for an additional week
(Fig. 1). In each study center, patients were block random-
ized on a 1:1 basis to either sequence A, starting with in-
sulin glargine (period 1; weeks 1–24) and then switching
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to NPH insulin (period 2; weeks 25–48); or to sequence B,
starting with NPH insulin (period 1) and then switching to
insulin glargine (period 2). A crossover design was chosen
to allow for patients to serve as their own controls.
Insulin glargine (Sanofi, Berlin, Germany) and NPH in-
sulin (Sanofi, Berlin, Germany) were injected with the
TactiPen® injector pen (Sanofi, Berlin, Germany), which is
a re-usable insulin delivery device. Insulin glargine was ad-
ministered by subcutaneous injection once daily, at any
time, but each day at the same time. NPH basal insulin
was administered at bedtime (21:00–23:00). If the NPH
dose was exceeding 30 IE and/or nocturnal hypoglycaemia
occured, the NPH dose was split into two doses. One dose
was injected at bedtime as described and the second dose
was given in the morning (07:00 – 09:00).
During the first week of the treatment phase (forced ti-
tration phase), insulin titration was carried out daily. The
titration target value was FBG ≤ 5.6 mmol/L. Patients in-
creased their insulin dose following a predefined titration
algorithm until the target FBG value was reached. The
starting doses were 10 units (U) of insulin glargine and 10
insulin units (I.U.) of NPH insulin per day. At 24 weeks,
patients were switched to their second insulin treatment
regimen, again following the predefined titration schedule.
Four-week titration schemes were used to obtain the same
glycemic treatment targets in both insulin therapy regi-
mens during each treatment period, a procedure which
was only limited by general limitations of diabetes treat-
ment, such as increasing hypoglycemia or other safety
aspects.
In addition to insulin treatment, one or a maximum of
two OHAs were allowed (metformin, sulfonylurea, or
dipetidyl peptidase (DPP)-IV inhibitors). The dosage of
the OHAs remained stable during the study period. In
case of postprandial blood glucose (PPG) values exceeding
11.1 mmol/L on two consecutive visits, treatment with
prandial short-acting insulin was allowed.
Adherence to the insulin titration algorithm was con-
firmed by self-report of the physician. Insulin treatment
adherence and adherence to OHA treatment of patients
were measured by self-report and by evaluating the
amounts of prescribed insulins and OHAs, respectively.
Efficacy and safety endpoints
The primary efficacy endpoint of this study was a com-
parison of insulin glargine and NPH insulin used in
BOT in terms of a composite DRQoL score, which was
assessed at the end of each of the two treatment periods.
The DRQoL consisted of a standardized and unweighted
ITEQ score (Cronbach’s α = 0.93) [18], a PAID question-
naire score (Cronbach’s α = 0.86) [19, 20], and the men-
tal health score of the SF-12® Health Survey [21]. The
ITEQ was used to assess a range of factors, including
leisure activities, sleep, weight control, and diabetes con-
trol, as well as general treatment satisfaction. The PAID
questionnaire was designed to evaluate diabetes-specific
emotional stress. The mental health score of the SF-12®
included questions to indicate overall mental health as
perceived by the patient. After converting the three sub-
scores from these questionnaires to values in a 0–100
range, the composite score was calculated using the fol-
lowing formula: DRQoL = 1/3 * (ITEQ + (100 − PAID) +
SF-12®). The range of values for DRQoL was 0–100, with
100 being the optimal value.
In addition to the composite DRQoL score, the indi-
vidual questionnaire scores, and those from the EuroQol
(EQ-5D) questionnaire [22, 23], and the Diabetes Treat-
ment Satisfaction Questionnaire status version (DTSQs),
Fig. 1 Study design. OAD, oral antidiabetic drugs / oral hypoglycemic agents corresponding to a maximum of 2 drugs out of metformin,
sulfonylurea or a DPP-IV inhibitor; NPH, neutral protamine Hagedorn
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were assessed. Each of the questionnaires was completed
at baseline, crossover visit, and end of study, except for
ITEQ which was not completed at baseline because par-
ticipants included had no prior insulin treatment. Further
secondary efficacy variables assessed the level of glycemic
control by evaluating HbA1c values, FBG, and 7-point
blood glucose profiles (determined by self-measured blood
glucose readings). Additional parameters assessed as sec-
ondary variables were body weight, waist circumference,
blood pressure, and lipids. Further secondary objectives
and assessments included hypoglycemic events (symptom-
atic and/or severe), total daily insulin doses, and the pa-
tients’ treatment preference for insulin glargine vs. NPH
insulin reported at the end of the study.
Safety endpoints were total number of serious adverse
events (SAE) and adverse events (AE), including all forms
of hypoglycemia, in particular, severe hypoglycemia (sec-
ondary efficacy endpoint), and localized pain, redness, or
inflammation at the injection site. A 7-day follow-up
period was used to ensure that all events that may have
been related to treatment were included.
Statistical considerations and analysis
In a previous cross-sectional study [16], different effect
sizes of insulin glargine compared to NPH insulin in
terms of SF-12®, PAID, and ITEQ scores were observed
(d = 0.10, 0.11, and 0.29, respectively). The average effect
size of all three scales was d = 0.166. Since the present
study had a crossover design, in which each participant
served as his/her own control, an effect size on the pri-
mary endpoint DRQoL of d = 0.20 was expected. Such
an effect can be detected with 90 % power using a paired
t-test with a significance level of 5 % and with 265 pa-
tient pairs. Considering a non-evaluable rate of 20 %, a
total of 332 patients were to be enrolled in order to have
265 patients (completing both treatments) evaluable for
the efficacy analysis.
The primary efficacy endpoint was evaluated by analysis
of covariance (ANCOVA). The model included fixed ef-
fects for treatment, sequence, and period (treatment by
sequence interaction), as well as a random effect to ac-
count for subjects within sequence. The Shapiro-Wilk test
was applied to test the model assumption of normality of
residuals at a critical level of 0.1. Statistical tests were
performed at a significance level of α = 0.05.
Wherever possible, secondary endpoints were evaluated
by analyzing changes from the start of the respective treat-
ment period to its end. If applicable, treatment compari-
sons for secondary efficacy variables were made by the
variance analytical approach described for the primary effi-
cacy endpoint. The number of patients with at least one
hypoglycemic event and the number of hypoglycemic
events per patient year of insulin treatment was analyzed.
Treatment differences in hypoglycemia rates were analyzed
using the McNemar test. The same test was used to
analyze response rates. For the questionnaires, single do-
main scores were summarized descriptively by treatment
period. The total scores were also analyzed by ANCOVA.
For the primary and secondary efficacy variables, two sub-
groups (by treatment sequence) were analyzed (within pa-
tient comparison): A) starting with insulin glargine and
then switching to NPH insulin, and B) starting with NPH
insulin and then switching to insulin glargine. In addition,
treatment comparisons were performed focusing on each
period separately (between patient comparisons).
Data entry, verification, and validation were carried
out using SAS version 9.2.
Results
Patient disposition, demographics, and disease
characteristics
A total of 460 patients at 39 centers throughout Germany
were screened for this study, of which 343 patients were
randomized to either sequence A (n = 176) starting with
insulin glargine or sequence B starting with NPH insulin
(n = 167). A total of 151 (85.8 %) patients in sequence A
and a total of 145 (86.8 %) patients in sequence B com-
pleted the study (Fig. 2). Of the 343 patients randomized,
340 received at least one dose of study drug (safety popu-
lation), 339 had the required post-baseline efficacy data
available (intention to treat; ITT), 229 had all values for
the primary endpoint evaluation (modified intention to
treat; mITT), and 224 had no major protocol violations
(per-protocol; PP).
Patients comprising the ITT population had a mean age
of 62.3 ± 9.0 years, 39.5 % were female, they had a high co-
morbidity burden, and the mean diabetes duration was
115.2 ± 71.0 months (equivalent to 9.6 ± 5.9 years), with
no major difference between treatment sequences A and
B (Table 1). Mean baseline HbA1c was 8.15 ± 0.72 %, and
mean FBG level was 9.37 ± 2.19 mmol/L, with negligible
differences between sequences.
Primary endpoint (DRQoL scores)
On a 0–100 scale, the mean DRQoL scores in period 1
were 69.7 ± 8.45 with insulin glargine (sequence A) and
69.8 ± 9.81 with NPH insulin (sequence B). In treatment
period 2, the mean scores were 69.4 ± 9.66 for insulin
glargine (sequence B) and 70.1 ± 9.04 for NPH insulin
(sequence A) (Table 2). When combining all data from
both periods for each insulin treatment, mean DRQoL
score was 69.6 ± 9.04 with insulin glargine and 70.0 ±
9.40 with NPH insulin. Neither an effect of treatment
with insulin glargine vs NPH insulin (p = 0.31) nor a
period effect (p = 0.96) nor a sequence effect (p = 0.76)
was observed using an ANCOVA. However, it should be
noted that model assumption of normally distributed re-
siduals was not fulfilled. Within-patient comparisons did
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Fig. 2 Patient disposition. No further data are available for patients not getting randomized
Table 1 Patient and disease characteristics (ITT population)
Sequence A (n = 175) Sequence B (n = 164) Total (n = 339)
Age in years, mean ± SD 61.9 ± 8.8 62.7 ± 9.2 62.3 ± 9.0
Female gender, % 38.3 40.9 39.5
Weight in kg, mean ± SD 90.1 ± 15.8 91.1 ± 15.1 90.5 ± 15.5
BMI in kg/m2, mean ± SD 30.9 ± 4.5 31.2 ± 4.7 31.0 ± 4.6
WC in cm, mean ± SD 106.4 ± 11.7 107.2 ± 11.4 106.8 ± 11.5
Diabetes duration in months, mean ± SD 115.1 ± 71.3 115.2 ± 71.0 115.2 ± 71.0
Diabetes duration in years, mean ± SD 9.6 ± 5.9 9.6 ± 5.9 9.6 ± 5.9
HbA1c in %, mean ± SD 8.17 ± 0.73 8.13 ± 0.72 8.15 ± 0.72
FBG in mmol/L, mean ± SD 9.24 ± 2.23 9.50 ± 2.16 9.37 ± 2.19
Time since first OHA treatment in months, mean ± SD 72.8 ± 62.2 67.3 ± 55.3 70.2 ± 58.9
Concomitant disease
Cardiac disorders, % 28.0 23.8 26.0
Vascular disorders, % 86.3 88.4 87.3
Renal and urinary disorders, % 24.6 18.3 21.5
Concomitant oral medication
Metformin, % 90.9 89.6 90.3
Sulfonylurea, % 57.7 54.9 56.3
DPP-IV inhibitors, % 22.3 26.2 24.2
Legend: Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin
glargine; SD, standard deviation; BMI, body mass index; WC, waist circumference; OHA, oral hypoglycemic agents; FBG, fasting blood glucose
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not show a treatment effect either for patients random-
ized to sequence A (p = 0.48) or for patients in sequence
B (p = 0.46) (Table 2). Between-patient comparisons did
not show a treatment effect either for the first treat-
ment period (p = 0.97) or for the second treatment
period (p = 0.55) (Table 2). Results were consistent in an
analysis of the PP population as well as in a sensitivity
analysis on the ITT population, where missing SF-12®
mental health scores were replaced by the corresponding
value reported at the baseline visit (data not shown).
Patient reported outcomes
For ITEQ, SF-12®, and EQ-5D, results were very similar
between the two treatments and the two periods (Table 3).
In line with the results of the primary endpoint, neither
treatment effect, nor period effect, nor sequence effect
was revealed by ANCOVA.
For the PAID questionnaire, no treatment effect (p =
0.71) and no sequence effect (p = 0.83), but a period effect
(p < 0.0001) was revealed. Values decreased during period
1 for both insulin types, indicating reductions in diabetes-
specific emotional distress (−5.1 ± 11.4 for sequence A
with insulin glargine, −4.4 ± 14.8 for sequence B with
NPH insulin. Only minor further changes occurred during
period 2 for both treatments (Table 3).
In terms of treatment satisfaction (DTSQs), ANCOVA
indicated a trend towards a treatment effect (p = 0.071),
but no sequence effect (p = 0.89). A highly significant
period effect (p < 0.0001) was also revealed. As shown in
Table 3, scores increased by 3.2 ± 8.04 for sequence A
with insulin glargine and 2.1 ± 7.36 for sequence B with
NPH insulin in treatment period 1, showing only minor
further changes during treatment period 2 (−0.8 ± 6.4 for
sequence A with NPH insulin and +0.3 ± 6.9 for se-
quence B with insulin glargine). There were no differ-
ences between the treatments in DTSQs subscales
focusing on hyper- or hypoglycemia (Table 3).
Glucose metabolism and body weight
Regarding the effects on glucose metabolism, no dif-
ferences between the two insulin types were observed
(Tables 4, 5). Mean HbA1c values decreased by 1.17 %
in the first treatment period for both insulin glargine
and NPH insulin. In the second period, HbA1c values in-
creased slightly compared to the crossover visit (0.21 %
and 0.09 % in sequences A and B, respectively). No treat-
ment effect (p = 0.65) or sequence effect (p = 0.17), but a
period effect (p < 0.0001) on HbA1c levels was revealed by
ANCOVA. Similarly, mean FBG was reduced in the first
period compared to baseline, and then reduced a little fur-
ther in the second period, with no significant differences
between treatments. However, in terms of achieving the
target of FBG ≤ 5.6 mmol/L, response rates were higher
for patients receiving insulin glargine compared to NPH
insulin (32.4 and 25.4 %, respectively; p = 0.02). For
HbA1c levels, response rates were numerically although
not significantly better for patients receiving insulin
glargine in comparison to NHP insulin, with target
HbA1c ≤ 7.0 % rates being 54.0 and 51.9 %, respectively
(p = 0.64), and ≤ 6.5 % rates being 26.3 and 24.5 %, re-
spectively (p = 0.69). Mean 7-point blood glucose profiles
are displayed in Fig. 3. In terms of changes in body weight,
neither a treatment effect (p = 0.97), nor a period effect
(p = 0.57), nor a sequence effect (p = 0.84) was revealed by
ANCOVA. Slight increases were observed during each
period (insulin glargine: 0.40 kg in period 1 and 0.73 kg in
period 2; NPH insulin: 0.51 kg in period 1 and 0.67 kg in
period 2).
Insulin use
Mean daily insulin glargine dose was 17.9 ± 11.5 U at the
end of the titration phase and was further increased by
7.3 ± 15.3 U during period 1. Similar values were ob-
tained for NPH insulin (17.4 ± 10.7 and 7.6 ± 9.5 I.U., re-
spectively). At the end of the titration phase of period 2,
mean daily insulin glargine dose was 22.4 ± 14.6 and was
further increased by 3.6 ± 6.6 U. Respective values ob-
tained for NPH insulin were 23.3 ± 16.9 with an increase
of 5.5 ± 8.4 I.U. ANCOVA results for change of insulin
dose from end of titration to end of period revealed a
small treatment effect (p = 0.041; increase in dose for
NPH insulin was more pronounced than for insulin glar-
gine) and a period effect (p < 0.0001; increase in dose
was more pronounced in period 1 than in period 2 for
both treatments), but no sequence effect (p = 0.56). At
the end of period 1, mean insulin doses were 24.9 ± 20.3
U for insulin glargine and 24.8 ± 15.7 I.U. for NPH insu-
lin, and at the end of period 2, the corresponding insulin
doses were 26.0 ± 17.0 U and 28.7 ± 20.1 I.U. Respective
values for insulin doses per kilogram bodyweight (kg
BW) were 0.27 ± 0.20 U/kg BW at the end of period 1
and 0.28 ± 0.16 U/kg BW at end of period 2 for insulin
Table 2 Summary of DRQoL scores [range 0–100] – between
and within patient comparison of treatments (mITT population)
End of period 1,
mean ± SD
End of period 2,
mean ± SD
p-value*
Sequence A 69.7 ± 8.45 70.1 ± 9.04 0.48
N = 118 (GLAR) (NPH)
Sequence B 69.8 ± 9.81 69.4 ± 9.66 0.46
N = 111 (NPH) (GLAR)
p-value ** 0.97 0.55
Legend: *Paired t-test was applied for comparison of treatments within each
sequence (within patient comparison); **Unpaired t-test was applied for
comparison of treatments in each period (between patient comparison);
Sequence A: starting with insulin glargine (GLAR) and then switching to NPH
insulin; Sequence B: starting with NPH insulin and then switching to
insulin glargine
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glargine and 0.27 ± 0.15 I.U./kg BW and 0.31 ± 0.21 I.U./
kg BW, respectively, for NPH insulin, showing no statis-
tically significant differences (Table 4).
With regard to treatment preference, more patients
continued the insulin treatment they received at the end
of the study than wished to change (at the end of period
2). However, more patients changed from NPH insulin
back to insulin glargine at the end of the study than vice
versa. Thus, in sequence A, 47.4 % of patients continued
on NPH insulin after the study, while 39.4 % switched
Table 3 Patient reported outcomes
Baseline (Visit 2) End of period 1 End of period 2 p-value*
ITEQ
Sequence A No insulin Tx 74.2 ± 11.8 73.3 ± 12.9 0.52
Sequence B No insulin Tx 73.0 ± 13.7 73.2 ± 12.0 0.74
p-value** 0.42 0.97
DTSQs Hyperglycemia
Sequence A 4.2 ± 1.53 2.2 ± 1.57 2.3 ± 1.76 n.a.
Sequence B 4.2 ± 1.60 2.2 ± 1.73 2.1 ± 1.70 n.a.
p-value** 1.0 0.32
DTSQs Hypoglycemia
Sequence A 0.7 ± 1.32 1.2 ± 1.57 1.3 ± 1.68 n.a.
Sequence B 0.6 ± 1.15 1.0 ± 1.47 1.1 ± 1.52 n.a.
p-value** 0.25 0.29
Baseline (Visit 2) Δ from baseline Δ from end of period 1 p-value*
PAID
Sequence A 21.3 ± 15.7 −5.1 ± 11.4 0.7 ± 10.4 <0.0001
Sequence B 23.3 ± 15.4 −4.4 ± 14.8 0.5 ± 11.7 0.0049
p-value** 0.61 0.89
SF-12® mental health
Sequence A 50.2 ± 9.34 0.5 ± 7.91 0.4 ± 7.56 0.68
Sequence B 49.8 ± 10.5 0.8 ± 9.21 −0.6 ± 8.59 0.24
p-value** 0.77 0.34
SF-12® physical health
Sequence A 50.5 ± 9.06 0.5 ± 7.94 −0.3 ± 8.04 n.a.
Sequence B 49.4 ± 9.20 0.9 ± 7.99 0.6 ± 7.29 n.a.
p-value** 0.70 0.36
EQ-5D descriptive
Sequence A 0.89 ± 0.16 −0.009 ± 0.1727 −0.005 ± 0.1787 0.91
Sequence B 0.900 ± 0.1682 0.001 ± 0.1606 −0.009 ± 0.1637 0.88
p-value** 0.62 0.85
EQ-5D VAS
Sequence A 0.867 ± 0.1730 −0.000 ± 0.1646 0.001 ± 0.1557 n.a.
Sequence B 0.862 ± 0.1819 0.009 ± 0.1655 −0.013 ± 0.1566 n.a.
p-value** 0.64 0.45
DTSQs
Sequence A 27.9 ± 7.72 3.2 ± 8.04 −0.8 ± 6.38 <0.0001
Sequence B 27.2 ± 7.37 2.1 ± 7.36 0.3 ± 6.92 0.0420
p-value** 0.22 0.16
Legend: * Paired t-test was applied for comparison of treatments within sequence; ** Unpaired t-test was applied for comparison of treatments in periods;
Sequence A: starting with insulin glargine (GLAR) and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin
glargine (GLAR)
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back to insulin glargine. In sequence B, 67.7 % continued
on insulin glargine and only 17.7 % switched back to
NPH insulin. The odds ratio of switching back is 3.03;
95 % CI, 1.79 - 5.20; p < 0.001 in favor of insulin
glargine.
Hypoglycemia outcomes
The proportions of patients with hypoglycemia (defined
as events in conjunction with a blood glucose measure-
ment of <3.1 mmol/L) were 17.7 % during treatment
with insulin glargine and 15.8 % during treatment with
NPH insulin (Table 6). A total of 21 patients (6.4 %)
experienced nocturnal hypoglycemia events during insu-
lin glargine treatment and 24 patients (7.4 %) during
NPH insulin treatment. Using a threshold of <3.9 mmol/
L, the rates of patients with overall hypoglycemia, day-
time hypoglycemia, and nocturnal hypoglycemia were
25.1 %, 20.5 %, and 7.6 %, respectively, during treatment
with insulin glargine; and 23.2 %, 18.3 %, and 10.8 %, re-
spectively, during treatment with NPH insulin. Two
patients, both in the NPH insulin group, reported events
that fulfilled the criteria for severe hypoglycemia (0.6 %
in the NPH insulin group). Numbers of hypoglyce-
mic events per patient year of insulin treatment re-
sulted in comparable rates of hypoglycemia in either
group, confirmed by blood glucose thresholds of <3.1
and <3.9 mmol/L. The mean number of events per patient
year was 0.87 (95 % CI, 0.73–1.04) for insulin glargine
and 0.81 (95 % CI, 0.67–0.97) using a threshold
of <3.1 mmol/L. The corresponding results using a thresh-
old of <3.9 mmol/L were 1.43 (95 % CI, 1.24–1.64) for in-
sulin glargine and 1.46 (95 % CI, 1.27–1.67) for NPH
insulin (Table 6). The evaluation of hypoglycemic events
using a threshold of < 3.1 mmol/L separated for each
period (Table 7) resulted in the following: in period 1
the proportion of patients with overall hypoglycemia
was 18.3 % during treatment with insulin glargine and
15.2 % during treatment with NPH insulin (OR = 1.24;
95 % CI, 0.70 – 2.21). In period 2 the proportion of
patients with overall hypoglycemia was 17.1 % during
treatment with insulin glargine and 16.4 % during
treatment with NPH insulin (OR = 1.06; 95 % CI,
0.58 – 1.92). Similar results were obtained using a
threshold < 3.9 mmol/L with a proportion of patients
with hypoglycemia of 25.1 % vs. 22.6 % (OR 1.15;
95%CI 0.70-1.90) in period 1 during treatment with in-
sulin glargine vs. NPH insulin and 25.0 % vs. 23.9 %
(OR 1.06; 95%CI 0.63-1.78) in period 2.
Safety
The overall profile of adverse events (AEs) was similar
for the two insulin treatments. Overall, 46.2 % and
43.2 % of the patients experienced at least one AE dur-
ing treatment with insulin glargine and NPH insulin, re-
spectively. Serious AEs were reported for 7.3 % and
5.2 % of the patients, respectively.
Four patients died during the study: three patients
during treatment with insulin glargine and one patient
during treatment with NPH insulin. None of the AEs
leading to death were considered as possibly related to
the investigational drug by the investigator. The reported
reasons for death were multiple organ failure, pancreatic
cancer, cardiovascular failure, and ‘natural’ death.
A total of 12 AEs leading to discontinuation were re-
ported for 6 patients (1.8 %) during treatment with insu-
lin glargine. During NPH insulin treatment a total of 6







FBG (before breakfast) in
mmol/L, mean ± SD
Sequence A 9.24 ± 2.23 6.48 ± 1.66 6.27 ± 1.32
Sequence B 9.50 ± 2.16 6.60 ± 1.82 6.15 ± 1.42
p-value* 0.55 0.46
Daily insulin doses in U,
mean ± SD
Sequence A 0 24.9 ± 20.3 28.7 ± 20.1
Sequence B 0 24.8 ± 15.7 26.0 ± 17.0
p-value* 0.96 0.21
Insulin doses by bodyweight
in U/kg, mean ± SD
Sequence A 0 0.27 ± 0.20 0.31 ± 0.21
Sequence B 0 0.27 ± 0.15 0.28 ± 0.16
p-value* 0.88 0.13
Legend: * Unpaired t-test was applied for comparison of treatments in periods;
Sequence A: starting with insulin glargine and then switching to NPH insulin;
Sequence B: starting with NPH insulin and then switching to insulin glargine










Sequence A 8.17 ± 0.73 −1.17 ± 1.05 0.21 ± 0.58 <0.0001
Sequence B 8.13 ± 0.72 −1.17 ± 0.93 0.09 ± 0.63 <0.0001
p-value** 0.97 0.10
Body weight
in kg, mean ± SD
Sequence A 90.1 ± 15.8 0.40 ± 3.31 0.67 ± 2.51 0.70
Sequence B 91.0 ± 15.13 0.51 ± 3.34 0.73 ± 3.10 0.68
p-value** 0.77 0.86
Legend: * Paired t-test was applied for comparison of treatments within
sequence; ** Unpaired t-test was applied for comparison of treatments in
periods; Sequence A: starting with insulin glargine and then switching to NPH
insulin; Sequence B: starting with NPH insulin and then switching to
insulin glargine
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AEs leading to discontinuation were reported for 5
patients (1.5 %).
Discussion
The principal aim of this study was to perform an intra-
individual comparison of insulin glargine and NPH insu-
lin with regard to patient reported outcomes such as
treatment satisfaction, quality of life, and diabetes-
specific emotional distress.
This randomized, controlled study was initiated owing
to the scarcity of data regarding PROs after BOT initi-
ation with insulin glargine or NPH insulin in type 2 dia-
betes patients. By using this crossover design, each
patient could serve as his/her own control, allowing for
direct comparison between the effects of the two drugs
on quality of life. The DRQoL composite score used was
designed to allow for a wide variety of PROs to be evalu-
ated simultaneously. The ITEQ includes questions re-
garding lifestyle and general treatment satisfaction, the
PAID questionnaire assesses diabetes-specific emotional
distress, and the SF-12® provides information regarding
the overall mental health of the patient. It was found
that there were no statistically significant differences in
DRQol score when making within-patient or between-
patient comparisons. Furthermore, negligible differences
were identified between the two treatment periods or
between sequence A and sequence B. Of the previous
evaluations of the effect of insulin glargine and NPH insu-
lin on quality of life, none have reported highly significant
differences between the two drugs. Hauner et al. described
a retrospective, non-interventional, cross-sectional study
(LIVE-DE) [16], where 1,602 patients (982 on insulin glar-
gine, 620 on NPH insulin) were assessed in terms of qual-
ity of life using the ITEQ, PAID, SF-12®, and DTSQs.
Patients treated with insulin glargine achieved statistically
significant higher scores on the ITEQ, and physical sub-
scale of the SF-12® questionnaire, with a trend towards su-
perior scores found for the DTSQs, PAID, and mental
health subscale of the SF-12®. However, retrospective, ob-
servational data such as those of the LIVE-DE study are
Fig. 3 7-point blood glucose profile (ITT). Meaurements: 1-before breakfast, 2-2 h after breakfast, 3-before lunch, 4-2 h after lunch, 5-before dinner,
7-before sleeping. Source: bgprofcurve.sas[SVN:20879] Date Extract: 08FEB2013 Table Generation: 10JUNE2013 15:21
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prone to bias because of no random treatment allocation,
and selection bias introduced by only being able to docu-
ment those with a complete follow-up. Furthermore, BOT
was only used in 43.0 % of insulin glargine and 16.3 % of
NPH insulin patients, with a basal-bolus strategy being
used in the majority of the remaining cases. In the present
study, no differences were found in ITEQ, SF-12®, or EQ-
5D scores when comparing treatments, periods, or se-
quences. In terms of the DTSQs score, a trend was
apparent towards a higher score for patients receiving
insulin glargine; however, the only statistically signifi-
cant difference identified was when comparing the two
treatment periods. Improved treatment satisfaction was
evident at the end of period 1, but only slight further
changes were found after switching to the other treatment.
In an open-label, 24-week, randomized controlled trial,
Eliaschewitz et al. investigated differences in treatment
satisfaction between patients randomized to treatment
with glimepiride in combination with either insulin glar-
gine or NPH insulin [8]. They observed better treatment
satisfaction with insulin glargine (p < 0.02), as assessed
using the DTSQ change version (DTSQc). Witthaus et
al. reported on a 1-year, multicenter, open-label clinical
study in 570 patients with type 2 diabetes that were ran-
domized to receive either insulin glargine or NPH insu-
lin, both in combination with oral agents [15, 24].
Patients completed the DTSQc and psychological Well
Being Questionnaire (W-BQ) at baseline and at regular
periods up to a year. Treatment satisfaction improved
significantly (p < 0.01) in both groups, showing a non-
significant tendency to be greater with insulin glargine
vs. NPH insulin (p = 0.0634).
Bradley et al. [25] investigated the responsiveness of
the DTSQc used in the trials by Eliaschewitz et al. and
by Witthaus et al. [8, 15, 24], and compared it to the ori-
ginal DTSQs which we used in our trial (as a secondary
endpoint). It was shown that, unlike in type 1 diabetes
patients, no major effect of treatment was seen for pa-
tients with type 2 diabetes. Based on their results they
concluded that benefits attributable to glargine, which
would not be revealed by the DTSQs alone, became ap-
parent on use of the DTSQc when used with people
Table 6 Hypoglycemia Outcomes (ITT population)
Episodes per patient year Hypoglycemia rates









(N = 327) (N = 323) (N = 327) (N = 323)
Total exposure time in yearsa 144.8 144.5
Threshold <3.1 mmol/L
Overall hypoglycemia 0.87 (0.73-1.04) 0.81 (0.67-0.97) 17.7 (13.8-22.3) 15.8 (12.0-20.2) 0.2492
Daytime hypoglycemia 0.59 (0.48-0.73) 0.49 (0.38-0.62) 12.8 (9.4-17.0) 12.1 (8.7-16.1) 0.4751
Nocturnal hypoglycemia 0.28 (0.20-0.38) 0.32 (0.23-0.42) 6.4 (4.0-9.6) 7.4 (4.8-10.9) 0.7150
Threshold <3.9 mmol/L
Overall hypoglycemia 1.43 (1.24-1.64) 1.46 (1.27-1.67) 25.1 (20.5-30.1) 23.2 (18.7-28.2) 0.2922
Daytime hypoglycemia 1.02 (0.86-1.20) 0.91 (0.76-1.08) 20.5 (16.2-25.3) 18.3 (14.2-22.9) 0.2253
Nocturnal hypoglycemia 0.41 (0.31-0.53) 0.55 (0.44-0.69) 7.6 (5.0-11-1) 10.8 (7.7-14.7) 0.1699
Severe hypoglycemiab 0.00 (NE-0.03) 0.01 (0.00-0.05) 0.0 (0.0-1.1) 0.6 (0.1-2.2) NA
Legend: *McNemar test applied; bone daytime event for each type of insulin; acalculated by adding the exposure time of each patient to each type of insulin
Table 7 Hypoglycemia Outcomes by treatment phase (ITT population)
Period 1 Period 2
Hypoglycemia Glar (N = 175) % NPH (N = 164) % OR (95%CI) Glar (N = 152) % NPH (N = 159) % OR (95%CI)
Threshold <3.1 mmol/L
Overall hypoglycemia 18.3 15.2 1.24 (0.70-2.21) 17.1 16.4 1.06 (0.58-1.92)
Daytime hypoglycemia 12.6 9.8 1.33 (0.67-2.63) 13.2 14.5 0.90 (0.47-1.71)
Nocturnal hypoglycemia 8.0 8.5 0.93 (0.43-2.02) 4.6 6.3 0.72 (0.27-1.94)
Threshold <3.9 mmol/L
Overall hypoglycemia 25.1 22.6 1.15 (0.70-1.90) 25.0 23.9 1.06 (0.63-1.78)
Daytime hypoglycemia 20.0 15.9 1.33 (0.76-2.32) 21.1 20.8 1.02 (0.59-1.76)
Nocturnal hypoglycemia 9.1 12.2 0.72 (0.36-1.45) 5.9 9.4 0.60 (0.26-1.43)
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scoring at or near floor at baseline. This finding may ex-
plain why greater differences in treatment satisfaction
were reported in the other trials than in the one presented
here. Another point of note is that glucose metabolism at
baseline was much poorer in the Eliaschewitz study in
comparison to our own. This detail is of relevance because
patients scored quite highly on the SF-12® and the PAID
questionnaires at baseline in the present study, potentially
making improvements harder to detect.
Based on the treatment algorithm with dedicated titra-
tion and concomitant pharmacotherapy, metabolic con-
trol was almost identical between treatment groups in
our study. HbA1c levels strongly decreased during
period 1, but slightly increased during period 2 for both
groups. This increase may be due to poorer treatment
adherence in the second period, or it could indicate that
titration algorithms were followed less rigorously. FBG
levels significantly improved in both groups from base-
line to the end of period 1, and then further decreased
in period 2. No statistically significant differences in
rates of hypoglycemia were evident. This finding is con-
sistent with the results obtained by Witthaus et al. [15,
24], where the decrease in HbA1c and the proportion of
patients experiencing hypoglycemia were similar in both
groups, and where trends for improved treatment satis-
faction with insulin glargine were non-significant. In the
study published by Eliaschewitz et al. [8], while equiva-
lence was found for the two treatment groups in terms
of changes in HbA1c levels from baseline (p = 0.795), a
27 % lower relative risk (RR) of hypoglycemia was dem-
onstrated for insulin glargine in comparison to NPH in-
sulin (RR, 1.27; 95 % CI, 1.03–1.57). Furthermore, the
proportion of patients that experienced nocturnal
hypoglycemia was much higher in the NPH insulin
group (RR, 1.22; 95 % CI, 1.09–1.37; p < 0.001). Greater
rates of hypoglycemia in patients receiving NPH insulin
in comparison to insulin glargine have been reported in
a similar magnitude in other trials [9, 10, 26]. The obser-
vation that patient groups who showed differences in
hypoglycemia also displayed differences in treatment satis-
faction, and vice versa those not showing differences in
hypoglycemia displayed similar levels, demonstrates the
significant influence of hypoglycemic events on the quality
of life of type 2 diabetes patients receiving BOT. This con-
clusion is supported by previous studies that have shown
strong associations between rates of hypoglycemia and
quality of life in patients with type 2 diabetes [27, 28].
A notable finding of our investigation is that at the end
of the 48 weeks of treatment, 39.4 % of patients receiving
NPH insulin during period 2 (sequence A) switched back
to insulin glargine. In contrast, only 17.7 % of patients re-
ceiving insulin glargine during period 2 (sequence B)
switched back to NPH insulin. This outcome may indicate
a limitation of the three questionnaires used to determine
the impact of insulin glargine on treatment choices and
patient reported outcomes.
The crossover design of this study enabled us to per-
form intra-individual comparisons of endpoint variables,
abolishing differences in patient groups such as those
seen in LIVE-DE and the Eliaschewitz study [8, 16].
Within this context, we opted to not perform a washout
phase, contrary to other studies [29, 30], because of con-
straints emerging from discontinuing insulin treatment
for a period of two weeks and restarting it thereafter.
For safety reasons we recommended patients in period 2
to receive approximately 80 % of the daily dose of the in-
sulin given before the crossover. The lack of washout
phase, on the other hand, bears the potential for a sub-
stantial carry-over effect from one treatment to the
other, with a potential reduction in differences in target
achievement and treatment satisfaction. Patients at base-
line were insulin naïve, while at the start of period 2,
they had received 24 weeks of insulin treatment. This as-
pect of the study design is likely to provide further con-
founding effects when comparing the questionnaire
scores at the end of the two treatment periods.
Another limitation of the study is that the treatment
target of FBG ≤ 5.6 mmol/L was only achieved in 32.4 %
of patients receiving insulin glargine and in 25.4 % of pa-
tients receiving NPH insulin. This result is in contrast to
the 74.6 % and 70.7 % of insulin glargine and NPH insu-
lin treated patients, respectively, reaching the FBG ≤
5.5 mmol/L target in the Eliaschewitz study [8]. There
was also a difference in mean insulin dose at the end of
these two studies, with lower doses being administered
in the present investigation. The failure to reach titration
goals in the majority of both treatment groups, along
with the lower doses of insulin, has the potential to
mask any advantages of glargine treatment with regard
to the avoidance of hypoglycemia and perceived benefits
from a patient perspective.
Concomitant OHA therapy was only weakly defined in
our study protocol. Only patients receiving one or a max-
imum of two oral hypoglycemic drugs (metformin, sulfo-
nylurea, or DPP-IV inhibitors) were allowed. Doses of
these were kept stable (±20 %) throughout the study, ex-
cept for cases of hypoglycemia, when they could be re-
duced. Moreover, additional prandial short-acting insulin
was allowed in cases of PPG values exceeding 11.1 mmol/L
on two consecutive visits. This latter aspect of the study
design may have led patients with difficulties in maintain-
ing their blood glucose levels to appear as being better con-
trolled than in fact they were, reducing the differences
observed between treatment strategies.
Clinical implications
The results of the present investigation indicate that
when leading to insufficient but equivalent glycemic
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control and only small differences in hypoglycemia rates,
insulin glargine and NPH insulin BOT provide similar
quality of life and treatment satisfaction with the instru-
ments used in this study. Deliberate omission of insulin
injections has been reported by substantial numbers of
patients, naming interference in lifestyle and problems
with injections to be factors associated with this [31].
Therefore, achieving optimal quality of life for patients
who require insulin therapy is of great importance. Initi-
ation of insulin treatment often distresses patients, many
of them perceiving it to be a result of personal failure in
terms of achieving glycemic control [12, 13, 32]. In
addition, it is in fact a sign of disease progression, which
could be quite depressing for many individuals. The re-
sults from our investigation suggest that neither of the
two types of insulin investigated provided significantly
greater reduction in diabetes-related emotional distress
when starting insulin therapy.
Due to the higher number of patients not reaching tar-
get glycemic control, previously reported differences in
incidence of hypoglycemia when comparing insulin glar-
gine and NPH insulin were not shown in the present
study. As this factor has been associated with a lower
quality of life, it appears that controlling hypoglycemia
may be the most important consideration when the
physician is selecting the type of insulin to prescribe.
Conclusions
This phase IV, crossover study was focused on the impact
of treatment with insulin glargine versus NPH insulin on
patients’ judgment in terms of treatment satisfaction and
quality of life using PROs. After treatment of the patients
with both insulin types for 24 weeks each, the study
demonstrated that insulin glargine and NPH insulin
yielded similar results on the primary evaluation criterion,
DRQoL. The results illustrate that, in a patient population
with suboptimal HbA1c and FBG levels at baseline, with
equivalent glycemic control, differences in the PRO ques-
tionnaires tested are negligible when comparing insulin
glargine and NPH insulin.
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